EMA Approves Eisai's Lenvatinib for Accelerated Assessment in Radioiodine-Refractory Differentiated Thyroid Cancer

http://www.marketwatch.com/story/ema-approves-eisais-lenvatinib-for-accelerated-assessment-in-radioiodine-refractory-differentiated-thyroid-cancer-2014-07-30